Search clinical trials for: Zolendronic Acid

Total 23922 results

Milton S. Hershey Medical Center
Novartis

Completed

Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL) (CTIBL)

Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

Osteoporosis | Hip Fracture

United States, Germany
Novartis Pharmaceuticals

Completed

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

Prostate Cancer

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Pain | Breast Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer

United States
Institut für Klinische Krebsforschung IKF GmbH...
EUSA Pharma, Inc.

Recruiting

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)

Leiomyosarcoma

Germany
Sheba Medical Center

Not yet recruiting

Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density

Spinal Cord Injuries | Osteoporosis Fracture
Karolinska Institutet

Unknown

Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints (PREVENT RA)

Seropositive Muskuloskeletal Complaints
Shriners Hospitals for Children
Novartis

Completed

An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta (INFOI)

Osteogenesis Imperfecta

Canada
Vejle Hospital
Odense University Hospital; Novartis

Completed

Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer

Breast Cancer | Multiple Myeloma

Denmark
Virginia Commonwealth University
Novartis

Withdrawn

Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Sickle Cell Disease

United States
Novartis Pharmaceuticals

Completed

HORIZON-PFT: Pivotal Fracture Trial

Osteoporosis

United States, Germany
University of Louisville
James Graham Brown Cancer Center

Terminated

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

Multiple Myeloma

United States
University of Pittsburgh
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Zoledronic Acid for Osteoporosis in the Elderly (ZEST)

Osteoporosis | Bone Loss | Fragility Fractures

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer

Prostate Cancer

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

Lung Metastases | Tumor Necrosis

China
Children's Hospital of Eastern Ontario

Completed

Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study

Osteoporosis

Canada
University of California, San Francisco
Novartis

Completed

Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer

United States
University of Wisconsin, Madison

Completed

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis

Osteoporosis

United States
Sun Yat-sen University
Novartis

Completed

Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

Non Small Cell Lung Cancer | Bone Metastases | High NTX Level

China
University of Colorado, Denver

Recruiting

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Carcinoma, Non-Small-Cell Lung

United States
Aarhus University Hospital

Recruiting

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)

Osteoporosis, Postmenopausal

Denmark
Shengjing Hospital
The People's Hospital of Liaoning Province; Liaoning Tumor Hospital & Institute

Recruiting

Study on Bisphosphonates Targeting Triple-negative Breast Cancer

Breast Cancer

China
Institut Cancerologie de l'Ouest

Completed

ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma (GEMO)

Prostate Adenocarcinoma

France
Centre Hospitalier Universitaire de Nice

Completed

Stage I Multiple Myeloma Treatment (IFM-01-04)

Multiple Myeloma

France
Mohammed Milhem
Rising Tide Foundation

Active, not recruiting

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Chondrosarcoma

United States
University of Sydney
Novartis

Unknown

Osteonecrosis of the Hip and Bisphosphonate Treatment (BONES)

Osteonecrosis

Australia
Medical University of Vienna

Unknown

Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation

Liver Transplantation | Osteoporosis

Austria
Aksaray University
Lund University Hospital

Recruiting

FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA

Hip Fractures | Trochanteric Fracture of Femur | Bone Density, Low | Osteoporotic Fracture of Femur

Turkey
Helse Stavanger HF
Helse-Bergen HF

Enrolling by invitation

Prospective Breast Cancer Biobanking (PBCB)

Breast Cancer

Norway
Australian and New Zealand Intensive Care Research...

Recruiting

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (BoneZone)

Critical Illness | Osteoporosis

Australia, New Zealand
University of Guadalajara
Hospital Civil de Guadalajara

Completed

Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men (OSZCO)

Secondary Osteoporosis

Mexico
Assistance Publique Hopitaux De Marseille

Completed

Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid

Hutchinson-Gilford Progeria Syndrome

France
Amgen

Completed

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Bone Metastases
Mel Shiuann-Sheng Lee
Novartis

Completed

Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

Functional Outcomes | Prevention of BMD Loss After THR | Serum Markers of Bone Turnover

Taiwan
Boston Children's Hospital
Merck Sharp & Dohme LLC; Schering-Plough; Eiger BioPharmaceuticals

Active, not recruiting

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Progeria

United States
Tianjin Medical University

Unknown

Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer (esozao)

Breast Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Stinus Gadegaard Hansen
Odense University Hospital; Research Unit of Health Sciences, Hospital of South... and other collaborators

Recruiting

Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS) (ZABAS)

Bone Loss | Muscle Atrophy | Bariatric Surgery

Denmark
First Affiliated Hospital, Sun Yat-Sen University

Terminated

Bone Loss Treatment From Adjuvant Zoledronate Efficacy (BLAZE)

Breast Neoplasms | Bone Loss

China
University of Louisville
James Graham Brown Cancer Center

Completed

Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis

Breast Cancer

United States
Mario Negri Institute for Pharmacological Research
Associazione Italiana per la Ricerca sul Cancro

Terminated

Pre-operative Zoledronate in Triple Negative Breast Cancer

Breast Cancer

Italy
University of California, San Francisco
National Cancer Institute (NCI)

Terminated

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

Cervical Cancer | Precancerous Condition

United States
Novartis Pharmaceuticals

Completed

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

Breast Cancer | Prostate Cancer | Bone Metastasis

Germany
Novartis Pharmaceuticals

Terminated

A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women

Germany
Central European Cooperative Oncology Group

Terminated

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

Prostate Cancer

Montenegro, Slovenia, Serbia, Russian Federation, Austria, Poland, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Lithuania, Romania, Slovakia, South Africa
Novartis

Completed

Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy

Breast Cancer

Canada
University of Edinburgh
NHS Lothian

Recruiting

Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid (TOPaZ)

Osteogenesis Imperfecta

United Kingdom, Ireland
University of Michigan Rogel Cancer Center
Novartis; Aventis Pharmaceuticals

Completed

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

Hormone-Refractory Prostate Cancer

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density

Breast Cancer | Osteoporosis

United States

Search clinical trials for: Zolendronic Acid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations